Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Poniard Given SFDA Approval for Phase III Cancer Trial

publication date: Mar 1, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Poniard Pharmaceuticals has been granted SFDA approval to conduct two Phase III trials in China of its lead drug candidate, picoplatin, as a treatment for second-line small cell lung cancer (SCLC) and second-line ovarian cancer. Poniard, which is a US company without any China operations, said the approval would increase the drug’s value to prospective development partners. More details....

Stock Symbol: (NSDQ: PARD)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...